Scarica l'app Stockscreener
787.32
3.40%
25.87
Dopo l'orario di chiusura:
789.50
2.18
+0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$761.45
Aprire:
$764.88
Volume 24 ore:
1.19M
Relative Volume:
1.10
Capitalizzazione di mercato:
$81.32B
Reddito:
$14.25B
Utile/perdita netta:
$4.58B
Rapporto P/E:
18.85
EPS:
41.7701
Flusso di cassa netto:
$3.88B
1 W Prestazione:
+8.54%
1M Prestazione:
+36.23%
6M Prestazione:
+33.82%
1 anno Prestazione:
+5.04%
Intervallo 1D:
$760.00
$790.57
Intervallo di 1 settimana:
$702.63
$790.57
Portata 52W:
$476.49
$800.99
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at Truist Financial - MarketBeat
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $770.00 at Scotiabank - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Buy Rating from Analysts at HSBC - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mediolanum International Funds Ltd - MarketBeat
Rhumbline Advisers Sells 2,508 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cetera Investment Advisers - MarketBeat
DCF Advisers LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Charles Schwab Investment Management Inc. Has $378.14 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
EU approves Sanofi and Regeneron’s Dupixent as first targeted therapy for chronic spontaneous urticaria - Seeking Alpha
Inside Regeneron’s 3-Million-Sample Bet On Collaborative Genomics - Citeline News & Insights
Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria - MarketScreener
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria - The Manila Times
Regeneron and Sanofi Announce European Commission Approval of Dupixent for Moderate-to-Severe Chronic Spontaneous Urticaria - Quiver Quantitative
FDA approves new EYLEA HD indication, expanded dosing intervals - Eyes On Eyecare
Truist Securities Lowers Price Target for Regeneron Pharmaceuticals (REGN) to $798 | REGN Stock News - GuruFocus
HSBC Initiates Buy Rating on Regeneron (REGN) with $890 Target - GuruFocus
Regeneron, Bayer Lose Eye Med Biosimilar Battle - Law360
Regeneron a new buy at HSBC on Eylea HD uptake, cancer therapy catalysts (REGN:NASDAQ) - Seeking Alpha
Scotiabank Raises Price Target for Regeneron Pharmaceuticals (RE - GuruFocus
1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month - Yahoo Finance
Mufg Securities Americas Inc. Has $1.21 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Truist Securities assumes coverage on Regeneron stock with Buy rating - Investing.com
HSBC Initiates Coverage on Regeneron Pharmaceuticals (REGN) with a 'Buy' Rating | REGN Stock News - GuruFocus
HSBC Initiates Regeneron Pharmaceuticals at Buy With $890 Price Target - MarketScreener
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Ensign Peak Advisors Inc - MarketBeat
Jim Cramer Says He "Should Have Been Recommending Regeneron" - Finviz
Jim Cramer Says He “Should Have Been Recommending Regeneron” - Insider Monkey
Tableaux LLC Takes $67.73 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Swiss National Bank Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
TD Waterhouse Canada Inc. Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Legal & General Group Plc Sells 7,452 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Handelsbanken Fonder AB Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN is CenterBook Partners LP's 9th Largest Position - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by DNB Asset Management AS - MarketBeat
Empowered Funds LLC Acquires 7,207 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Sells 1,845 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
A Fresh Look at Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Expands Eylea HD’s Market Potential - simplywall.st
Jim Cramer Answered Questions About These 7 Stocks - Insider Monkey
Franklin Resources Inc. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Are Shares of Regeneron Attractive After Recent Surge on Clinical Trial Success? - Yahoo Finance
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Entropy Technologies LP - MarketBeat
ABN AMRO Bank N.V. Purchases New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Trading 4.6% Higher on Analyst Upgrade - MarketBeat
UC Berkeley dean’s research inspires emerging treatment for rare bone disease - University of California, Berkeley
Wells Fargo & Company Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $700.00 - MarketBeat
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO - Ophthalmology Times
Wealthspire Advisors LLC Sells 3,213 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock? - Barchart.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Vanguard Group Inc. - MarketBeat
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.02%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):